{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:46Z","timestamp":1792783426918,"version":"4.5.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Aristotle University of Thessaloniki","id":[{"id":"https:\/\/ror.org\/02j61yw88","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40265-026-02362-6","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T01:28:12Z","timestamp":1787275692000},"page":"1619-1643","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-invasive Assessment and Therapeutic Targeting in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Overcoming the Dissonance Between Drug Development and Precision Medicine"],"prefix":"10.1007","volume":"86","author":[{"given":"Eleni","family":"Theocharidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Arvanitakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theocharis","family":"Koufakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Tsochatzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-3118","authenticated-orcid":false,"given":"Georgios","family":"Germanidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"2362_CR1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"key":"2362_CR2","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/s0140-6736(24)01811-7","volume":"404","author":"M Israelsen","year":"2024","unstructured":"Israelsen M, Francque S, Tsochatzis EA, Krag A. Steatotic liver disease. Lancet. 2024;404:1761\u201378. https:\/\/doi.org\/10.1016\/s0140-6736(24)01811-7.","journal-title":"Lancet"},{"key":"2362_CR3","doi-asserted-by":"publisher","unstructured":"Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2023;21:619\u201329.e7. https:\/\/doi.org\/10.1016\/j.cgh.2021.11.038.","DOI":"10.1016\/j.cgh.2021.11.038"},{"key":"2362_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00599-1","volume":"11","author":"DQ Huang","year":"2025","unstructured":"Huang DQ, Wong VWS, Rinella ME, Boursier J, Lazarus JV, Yki-J\u00e4rvinen H, et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025;11:14. https:\/\/doi.org\/10.1038\/s41572-025-00599-1.","journal-title":"Nat Rev Dis Primers"},{"key":"2362_CR5","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321. https:\/\/doi.org\/10.1002\/hep.20701.","journal-title":"Hepatology"},{"key":"2362_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41575-024-00955-8","volume":"21","author":"JM Peric\u00e0s","year":"2024","unstructured":"Peric\u00e0s JM, Anstee QM, Augustin S, Bataller R, Berzigotti A, Ciudin A, et al. A roadmap for clinical trials in MASH-related compensated cirrhosis. Nat Rev Gastroenterol Hepatol. 2024;21:809\u201323. https:\/\/doi.org\/10.1038\/s41575-024-00955-8.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2362_CR7","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jhep.2022.07.004","volume":"77","author":"AM Allen","year":"2022","unstructured":"Allen AM, Therneau TM, Ahmed OT, Gidener T, Mara KC, Larson JJ, et al. Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design. J Hepatol. 2022;77:1237\u201345. https:\/\/doi.org\/10.1016\/j.jhep.2022.07.004.","journal-title":"J Hepatol"},{"key":"2362_CR8","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003520","author":"M Souza","year":"2025","unstructured":"Souza M, Al-Sharif L, Diaz I, Khalil SM. Enrollment in metabolic dysfunction-associated steatohepatitis clinical trials: a pooled analysis of screen failure rates. Am J Gastroenterol. 2025. https:\/\/doi.org\/10.14309\/ajg.0000000000003520.","journal-title":"Am J Gastroenterol"},{"key":"2362_CR9","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557\u201365. https:\/\/doi.org\/10.1002\/hep.29085.","journal-title":"Hepatology"},{"key":"2362_CR10","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.jhep.2022.04.002","volume":"76","author":"V Ratziu","year":"2022","unstructured":"Ratziu V, Francque S, Sanyal A. Breakthroughs in therapies for NASH and remaining challenges. J Hepatol. 2022;76:1263\u201378. https:\/\/doi.org\/10.1016\/j.jhep.2022.04.002.","journal-title":"J Hepatol"},{"key":"2362_CR11","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","volume":"79","author":"F Tacke","year":"2023","unstructured":"Tacke F, Puengel T, Loomba R, Friedman SL. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J Hepatol. 2023;79:552\u201366. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.038.","journal-title":"J Hepatol"},{"key":"2362_CR12","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/hep.30418","volume":"70","author":"EM Brunt","year":"2019","unstructured":"Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA. Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the Nonalcoholic Steatohepatitis Clinical Research Network treatment trials. Hepatology. 2019;70:522\u201331. https:\/\/doi.org\/10.1002\/hep.30418.","journal-title":"Hepatology"},{"key":"2362_CR13","doi-asserted-by":"publisher","first-page":"e1912565","DOI":"10.1001\/jamanetworkopen.2019.12565","volume":"2","author":"DE Kleiner","year":"2019","unstructured":"Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw Open. 2019;2:e1912565. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.12565.","journal-title":"JAMA Netw Open"},{"key":"2362_CR14","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cld.2023.01.010","volume":"27","author":"S Francque","year":"2023","unstructured":"Francque S, Ratziu V. Future treatment options and regimens for nonalcoholic fatty liver disease. Clin Liver Dis. 2023;27:429\u201349. https:\/\/doi.org\/10.1016\/j.cld.2023.01.010.","journal-title":"Clin Liver Dis"},{"key":"2362_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389-97.e10. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.043.","journal-title":"Gastroenterology"},{"key":"2362_CR16","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jhep.2024.08.031","volume":"82","author":"N Alkhouri","year":"2025","unstructured":"Alkhouri N, Beyer C, Shumbayawonda E, Andersson A, Yale K, Rolph T, et al. Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH. J Hepatol. 2025;82:438\u201345. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.031.","journal-title":"J Hepatol"},{"key":"2362_CR17","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ultrasmedbio.2025.05.020","volume":"51","author":"R Cannella","year":"2025","unstructured":"Cannella R, Matteini F, Gagliano DS, Mazzola M, Agnello F, Soresi M, et al. Performance of ultrasound liver fat quantification for the assessment of hepatic steatosis using MRI fat fraction as a reference standard. Ultrasound Med Biol. 2025;51:1495\u2013502. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2025.05.020.","journal-title":"Ultrasound Med Biol"},{"key":"2362_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.17476\/jmbs.2025.14.1.53","volume":"14","author":"JH Park","year":"2025","unstructured":"Park JH, Kim SM, Lee DH. Comparison of non-invasive methods for diagnosis of non-alcoholic fatty liver disease before bariatric surgery and postoperative follow-up in obese patients. J Metab Bariatr Surg. 2025;14:53\u201364. https:\/\/doi.org\/10.17476\/jmbs.2025.14.1.53.","journal-title":"J Metab Bariatr Surg"},{"key":"2362_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.20524\/aog.2024.0910","volume":"37","author":"K Malandris","year":"2024","unstructured":"Malandris K, Katsoula A, Liakos A, Bekiari E, Karagiannis T, Theocharidou E, et al. Accuracy of controlled attenuation parameter for liver steatosis in patients at risk for metabolic dysfunction-associated steatotic liver disease using magnetic resonance imaging: a systematic review and meta-analysis. Ann Gastroenterol. 2024;37:579\u201387. https:\/\/doi.org\/10.20524\/aog.2024.0910.","journal-title":"Ann Gastroenterol"},{"key":"2362_CR20","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s10620-024-08799-7","volume":"70","author":"K Malandris","year":"2025","unstructured":"Malandris K, Korakas E, Sarakapina A, Kalopitas G, Iatridi F, Liakos A, et al. Accuracy of controlled attenuation parameter for liver steatosis in high-risk patients for MASLD using MRI-proton density fat fraction as reference standard. Dig Dis Sci. 2025;70:814\u201324. https:\/\/doi.org\/10.1007\/s10620-024-08799-7.","journal-title":"Dig Dis Sci"},{"key":"2362_CR21","doi-asserted-by":"publisher","unstructured":"Petroff D, Blank V, Newsome PN, Shalimar, Voican CS, Thiele M, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:185\u201398. https:\/\/doi.org\/10.1016\/s2468-1253(20)30357-5","DOI":"10.1016\/s2468-1253(20)30357-5"},{"key":"2362_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/s2468-1253(20)30367-8","volume":"6","author":"G Ferraioli","year":"2021","unstructured":"Ferraioli G. CAP for the detection of hepatic steatosis in clinical practice. Lancet Gastroenterol Hepatol. 2021;6:151\u20132. https:\/\/doi.org\/10.1016\/s2468-1253(20)30367-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2362_CR23","doi-asserted-by":"publisher","DOI":"10.1172\/jci198334","author":"N Krahmer","year":"2025","unstructured":"Krahmer N, Walther TC, Farese RV Jr. The pathogenesis of hepatic steatosis in MASLD: a lipid droplet perspective. J Clin Invest. 2025. https:\/\/doi.org\/10.1172\/jci198334.","journal-title":"J Clin Invest"},{"key":"2362_CR24","doi-asserted-by":"publisher","DOI":"10.1172\/jci186420","author":"GR Steinberg","year":"2025","unstructured":"Steinberg GR, Carpentier AC, Wang D. MASH: the nexus of metabolism, inflammation, and fibrosis. J Clin Invest. 2025. https:\/\/doi.org\/10.1172\/jci186420.","journal-title":"J Clin Invest"},{"key":"2362_CR25","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","volume":"1","author":"A Gastaldelli","year":"2019","unstructured":"Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 2019;1:312\u201328. https:\/\/doi.org\/10.1016\/j.jhepr.2019.07.002.","journal-title":"JHEP Rep."},{"key":"2362_CR26","doi-asserted-by":"publisher","DOI":"10.1172\/jci174233","author":"JE Lambert","year":"2025","unstructured":"Lambert JE, Ramos-Roman MA, Valdez MJ, Browning JD, Rogers T, Parks EJ. Weight loss in MASLD restores the balance of liver fatty acid sources. J Clin Invest. 2025. https:\/\/doi.org\/10.1172\/jci174233.","journal-title":"J Clin Invest"},{"key":"2362_CR27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1053\/j.gastro.2025.02.034","volume":"169","author":"WY Liu","year":"2025","unstructured":"Liu WY, Huang S, Ji H, Kim SU, Yip TC, Wong GL, et al. From \u2018burnt-out\u2019 to \u2018burning-out\u2019: capturing liver fat loss in patients with advanced metabolic dysfunction-associated steatotic liver disease from a dynamic perspective. Gastroenterology. 2025;169:326-336.e4. https:\/\/doi.org\/10.1053\/j.gastro.2025.02.034.","journal-title":"Gastroenterology"},{"key":"2362_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/hep.27173","volume":"60","author":"P Bedossa","year":"2014","unstructured":"Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565\u201375. https:\/\/doi.org\/10.1002\/hep.27173.","journal-title":"Hepatology"},{"key":"2362_CR29","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.jhep.2024.11.032","volume":"82","author":"D Abdurrachim","year":"2025","unstructured":"Abdurrachim D, Lek S, Ong CZL, Wong CK, Zhou Y, Wee A, et al. Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH. J Hepatol. 2025;82:898\u2013908. https:\/\/doi.org\/10.1016\/j.jhep.2024.11.032.","journal-title":"J Hepatol"},{"key":"2362_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384. https:\/\/doi.org\/10.1002\/hep.28431.","journal-title":"Hepatology"},{"key":"2362_CR31","doi-asserted-by":"publisher","unstructured":"Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643\u201354.e1\u20139; quiz e39\u201340. https:\/\/doi.org\/10.1016\/j.cgh.2014.04.014.","DOI":"10.1016\/j.cgh.2014.04.014"},{"key":"2362_CR32","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jhep.2024.10.015","volume":"82","author":"Q Huang","year":"2025","unstructured":"Huang Q, Qadri SF, Bian H, Yi X, Lin C, Yang X, et al. A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease. J Hepatol. 2025;82:781\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2024.10.015.","journal-title":"J Hepatol"},{"key":"2362_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2019.154005","volume":"101","author":"N Perakakis","year":"2019","unstructured":"Perakakis N, Polyzos SA, Yazdani A, Sala-Vila A, Kountouras J, Anastasilakis AD, et al. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study. Metabolism. 2019;101:154005. https:\/\/doi.org\/10.1016\/j.metabol.2019.154005.","journal-title":"Metabolism"},{"key":"2362_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612717","author":"G Kalopitas","year":"2023","unstructured":"Kalopitas G, Mouskeftara T, Liapikos T, Arvanitakis K, Ioannidis A, Malandris K, et al. Plasma lipids profile in the prediction of non-alcoholic steatohepatitis in adults: a case-control study. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241612717.","journal-title":"Int J Mol Sci"},{"key":"2362_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115965","author":"T Mouskeftara","year":"2024","unstructured":"Mouskeftara T, Kalopitas G, Liapikos T, Arvanitakis K, Germanidis G, Gika H. Predicting non-alcoholic steatohepatitis: a lipidomics-driven machine learning approach. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25115965.","journal-title":"Int J Mol Sci"},{"key":"2362_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156296","volume":"169","author":"K Stefanakis","year":"2025","unstructured":"Stefanakis K, George J, Mantzoros CS. Non-invasive diagnosis and prognosis of MASH with fibrosis F2-F3: in need for a tailored, accessible, and affordable solution for the 21st century public health epidemic. Metabolism. 2025;169:156296. https:\/\/doi.org\/10.1016\/j.metabol.2025.156296.","journal-title":"Metabolism"},{"key":"2362_CR37","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.cgh.2022.03.044","volume":"21","author":"F Tavaglione","year":"2023","unstructured":"Tavaglione F, Jamialahmadi O, De Vincentis A, Qadri S, Mowlaei ME, Mancina RM, et al. Development and validation of a score for fibrotic nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2023;21:1523\u201332.e1. https:\/\/doi.org\/10.1016\/j.cgh.2022.03.044.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2362_CR38","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/apt.14621","volume":"47","author":"J Boursier","year":"2018","unstructured":"Boursier J, Anty R, Vonghia L, Moal V, Vanwolleghem T, Canivet CM, et al. Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH. Aliment Pharmacol Ther. 2018;47:1387\u201396. https:\/\/doi.org\/10.1111\/apt.14621.","journal-title":"Aliment Pharmacol Ther"},{"key":"2362_CR39","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jhep.2023.04.031","volume":"79","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Ratziu V, Magnanensi J, Hajji Y, Deledicque S, Majd Z, et al. NIS2+TM, an optimisation of the blood-based biomarker NIS4\u00ae technology for the detection of at-risk NASH: a prospective derivation and validation study. J Hepatol. 2023;79:758\u201367. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.031.","journal-title":"J Hepatol"},{"key":"2362_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101011","volume":"6","author":"QM Anstee","year":"2024","unstructured":"Anstee QM, Magnanensi J, Hajji Y, Caron A, Majd Z, Rosenquist C, et al. Impact of age on NIS2+TM and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH. JHEP Rep. 2024;6:101011. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101011.","journal-title":"JHEP Rep."},{"key":"2362_CR41","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/hep.0000000000000542","volume":"79","author":"M Noureddin","year":"2024","unstructured":"Noureddin M, Truong E, Mayo R, Mart\u00ednez-Arranz I, Minchol\u00e9 I, Banales JM, et al. Serum identification of at-risk MASH: the metabolomics-advanced steatohepatitis fibrosis score (MASEF). Hepatology. 2024;79:135\u201348. https:\/\/doi.org\/10.1097\/hep.0000000000000542.","journal-title":"Hepatology"},{"key":"2362_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156082","volume":"163","author":"K Stefanakis","year":"2025","unstructured":"Stefanakis K, Mingrone G, George J, Mantzoros CS. Accurate non-invasive detection of MASH with fibrosis F2\u2013F3 using a lightweight machine learning model with minimal clinical and metabolomic variables. Metabolism. 2025;163:156082. https:\/\/doi.org\/10.1016\/j.metabol.2024.156082.","journal-title":"Metabolism"},{"key":"2362_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102310","volume":"66","author":"V-S Wong","year":"2023","unstructured":"Wong V-S, Anstee QM, Nitze LM, Geerts A, George J, Nolasco V, et al. FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial. EClinicalMedicine. 2023;66:102310. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102310.","journal-title":"EClinicalMedicine"},{"key":"2362_CR44","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/s2468-1253(19)30383-8","volume":"5","author":"PN Newsome","year":"2020","unstructured":"Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, Yilmaz Y, Czernichow S, Zheng MH, Wong VW, et al. FibroScan-AST (FAST) Score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5:362\u201373. https:\/\/doi.org\/10.1016\/s2468-1253(19)30383-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2362_CR45","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","volume":"5","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Ratziu V, Boursier J, Francque S, Bedossa P, Majd Z, Cordonnier G, Sudrik FB, Darteil R, Liebe R, et al. A blood-based biomarker panel(NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. LancetGastroenterol Hepatol. 2020;5:970\u201385. https:\/\/doi.org\/10.1016\/S2468-1253(20)30252-1.","journal-title":"LancetGastroenterol. Hepatol."},{"key":"2362_CR46","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1016\/j.cgh.2023.03.032","volume":"21","author":"CM Canivet","year":"2023","unstructured":"Canivet CM, Zheng MH, Qadri S, Vonghia L, Chuah KH, Costentin C, George J, Armandi A, Adams LA, Lange NF, et al. Validation of the blood test MACK-3 for the noninvasive diagnosis of fibrotic nonalcoholic steatohepatitis: an international study with 1924 patients. Clinical Gastroenterology and Hepatology. 2023;21:3097\u2013106.e10. https:\/\/doi.org\/10.1016\/j.cgh.2023.03.032.","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"2362_CR47","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/s2468-1253(23)00017-1","volume":"8","author":"Y Vali","year":"2023","unstructured":"Vali Y, Lee J, Boursier J, Petta S, Wonders K, Tiniakos D, et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol. 2023;8:714\u201325. https:\/\/doi.org\/10.1016\/s2468-1253(23)00017-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2362_CR48","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1038\/s41591-023-02539-6","volume":"29","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Shankar SS, Yates KP, Bolognese J, Daly E, Dehn CA, et al. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis. Nat Med. 2023;29:2656\u201364. https:\/\/doi.org\/10.1038\/s41591-023-02539-6.","journal-title":"Nat Med"},{"key":"2362_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101351","volume":"7","author":"J Fichez","year":"2025","unstructured":"Fichez J, Mouillot T, Vonghia L, Costentin C, Moreau C, Roux M, et al. Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials. JHEP Rep. 2025;7:101351. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101351.","journal-title":"JHEP Rep"},{"key":"2362_CR50","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jhep.2023.10.038","volume":"80","author":"V Ratziu","year":"2024","unstructured":"Ratziu V, Harrison SA, Hajji Y, Magnanensi J, Petit S, Majd Z, et al. NIS2+TM as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials. J Hepatol. 2024;80:209\u201319. https:\/\/doi.org\/10.1016\/j.jhep.2023.10.038.","journal-title":"J Hepatol"},{"key":"2362_CR51","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0168-8278(25)00298-3","volume":"82","author":"M Pavlides","year":"2025","unstructured":"Pavlides M, Vali Y, Mozes F, Wonders K, Akthar S, Aithal G, et al. GS-001 Diagnostic performance of imaging and serum based MASLD biomarkers: robust validation in the prospective LITMUS imaging study. J Hepatol. 2025;82:S1-2. https:\/\/doi.org\/10.1016\/S0168-8278(25)00298-3.","journal-title":"J Hepatol"},{"key":"2362_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-335598","author":"V Ratziu","year":"2025","unstructured":"Ratziu V, Surabattula R, Bugianesi E, Schattenberg JMM, Myneni S, Rosso C, et al. Thrombospondin-2 is a performant biomarker of at-risk MASH and advanced MASH fibrosis in a large multicentre European cohort. Gut. 2025. https:\/\/doi.org\/10.1136\/gutjnl-2025-335598.","journal-title":"Gut"},{"key":"2362_CR53","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","volume":"22","author":"M Noureddin","year":"2024","unstructured":"Noureddin M, Charlton MR, Harrison SA, Bansal MB, Alkhouri N, Loomba R, et al. Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis. Clin Gastroenterol Hepatol. 2024;22:2367\u201377. https:\/\/doi.org\/10.1016\/j.cgh.2024.07.003.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2362_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.02.014","author":"K John","year":"2025","unstructured":"John K, Franck M, Geier A, Schattenberg JM, Schulze-Osthoff K, Bantel H. Non-invasive identification of metabolic dysfunction-associated steatotic liver disease patients eligible for resmetirom treatment. Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2025.02.014.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2362_CR55","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/gutjnl-2023-331401","volume":"73","author":"R Loomba","year":"2024","unstructured":"Loomba R, Amangurbanova M, Bettencourt R, Madamba E, Siddiqi H, Richards L, et al. MASH resolution index: development and validation of a non-invasive score to detect histological resolution of MASH. Gut. 2024;73:1343\u20139. https:\/\/doi.org\/10.1136\/gutjnl-2023-331401.","journal-title":"Gut"},{"key":"2362_CR56","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001396","author":"R Loomba","year":"2025","unstructured":"Loomba R, Daniel PCN, Amangurbanova M, Bettencourt R, Madamba E, Siddiqi H, et al. Head-to-head comparison of MASH resolution index versus FAST for non-invasive prediction of resolution of MASH on biopsy. Hepatology. 2025. https:\/\/doi.org\/10.1097\/hep.0000000000001396.","journal-title":"Hepatology"},{"key":"2362_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100929","author":"G Feng","year":"2025","unstructured":"Feng G, Boursier J, de Saint Loup M, Yilmaz Y, Takahashi H, Isoda H, et al. Fibrotic MASH resolutionVCTE index to diagnose fibrotic MASH resolution and predict LREs: a global multicenter study. Med. 2025. https:\/\/doi.org\/10.1016\/j.medj.2025.100929.","journal-title":"Med"},{"key":"2362_CR58","doi-asserted-by":"publisher","unstructured":"Wernberg CW, Indira Chandran V, Lauridsen MM, Skytthe MK, Hansen CD, Hansen JK, et al. Ability of soluble TREM2 and PRO-C3 as biomarkers to predict changes in MASLD activity. JHEP Rep [Internet]. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101432.","DOI":"10.1016\/j.jhepr.2025.101432"},{"key":"2362_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.03.003","author":"A Andersson","year":"2025","unstructured":"Andersson A, Loomba R, Beyer C, Mouchti S, Vuppalanchi R, Harisinghani M, et al. Change in cT1 following interventions in MASLD: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2025.03.003.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2362_CR60","doi-asserted-by":"publisher","unstructured":"Sanyal AJ, Ratziu V, Hajji Y, Magnanensi J, Deledicque S, Majd Z, et al. Serial measurements of NIS2+\u00ae enable monitoring disease evolution in patients with MASH: A retrospective cohort analysis. Hepatol Commun [Internet]. 2025 [cited 2026 Jun 15];9:e0844. https:\/\/doi.org\/10.1097\/HC9.0000000000000844.","DOI":"10.1097\/HC9.0000000000000844"},{"key":"2362_CR61","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385:1559\u201369. https:\/\/doi.org\/10.1056\/NEJMoa2029349.","journal-title":"N Engl J Med"},{"key":"2362_CR62","doi-asserted-by":"publisher","unstructured":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"2362_CR63","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jhep.2024.05.021","volume":"81","author":"M Papatheodoridi","year":"2024","unstructured":"Papatheodoridi M, De Ledinghen V, Lupsor-Platon M, Bronte F, Boursier J, Elshaarawy O, et al. Agile scores in MASLD and ALD: external validation and their utility in clinical algorithms. J Hepatol. 2024;81:590\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2024.05.021.","journal-title":"J Hepatol"},{"key":"2362_CR64","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jhep.2020.11.050","volume":"74","author":"M Papatheodoridi","year":"2021","unstructured":"Papatheodoridi M, Hiriart JB, Lupsor-Platon M, Bronte F, Boursier J, Elshaarawy O, et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol. 2021;74:1109\u201316. https:\/\/doi.org\/10.1016\/j.jhep.2020.11.050.","journal-title":"J Hepatol"},{"key":"2362_CR65","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/hep.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u2013835. https:\/\/doi.org\/10.1097\/hep.0000000000000323.","journal-title":"Hepatology"},{"key":"2362_CR66","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/s2468-1253(23)00141-3","volume":"8","author":"FE M\u00f3zes","year":"2023","unstructured":"M\u00f3zes FE, Lee JA, Vali Y, Alzoubi O, Staufer K, Trauner M, et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:704\u201313. https:\/\/doi.org\/10.1016\/s2468-1253(23)00141-3.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2362_CR67","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0140-6736(23)01174-1","volume":"402","author":"M Serra-Burriel","year":"2023","unstructured":"Serra-Burriel M, Juanola A, Serra-Burriel F, Thiele M, Graupera I, Pose E, et al. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. The Lancet. 2023;402:988\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(23)01174-1.","journal-title":"The Lancet"},{"key":"2362_CR68","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S2468-1253(24)00274-7","volume":"10","author":"KP Lindvig","year":"2025","unstructured":"Lindvig KP, Thorhauge KH, Hansen JK, Kj\u00e6rgaard M, Hansen CD, Johansen S, et al. Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study. Lancet Gastroenterol Hepatol. 2025;10:55\u201367. https:\/\/doi.org\/10.1016\/S2468-1253(24)00274-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2362_CR69","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jhep.2022.10.034","volume":"78","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Foucquier J, Younossi ZM, Harrison SA, Newsome PN, Chan WK, et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based agile scores. J Hepatol. 2023;78:247\u201359. https:\/\/doi.org\/10.1016\/j.jhep.2022.10.034.","journal-title":"J Hepatol"},{"key":"2362_CR70","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jhep.2024.11.049","volume":"82","author":"P Cal\u00e8s","year":"2025","unstructured":"Cal\u00e8s P, Canivet CM, Costentin C, Lannes A, Oberti F, Fouchard I, et al. A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD. J Hepatol. 2025;82:794\u2013804. https:\/\/doi.org\/10.1016\/j.jhep.2024.11.049.","journal-title":"J Hepatol"},{"key":"2362_CR71","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1053\/j.gastro.2024.03.017","volume":"167","author":"LA van Kleef","year":"2024","unstructured":"van Kleef LA, Francque SM, Prieto-Ortiz JE, Sonneveld MJ, Sanchez-Luque CB, Prieto-Ortiz RG, et al. Metabolic dysfunction-associated fibrosis 5 (MAF-5) score predicts liver fibrosis risk and outcome in the general population with metabolic dysfunction. Gastroenterology. 2024;167:357-367.e9. https:\/\/doi.org\/10.1053\/j.gastro.2024.03.017.","journal-title":"Gastroenterology"},{"key":"2362_CR72","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001356","author":"LA van Kleef","year":"2025","unstructured":"van Kleef LA, Pustjens J, Schattenberg JM, Holleboom AG, Castro Cabezas M, Tushuizen ME, et al. Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction. Hepatology. 2025. https:\/\/doi.org\/10.1097\/hep.0000000000001356.","journal-title":"Hepatology"},{"key":"2362_CR73","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003432","author":"N Alkhouri","year":"2025","unstructured":"Alkhouri N, Cheuk-Fung Yip T, Castera L, Takawy M, Adams LA, Verma N, et al. ALADDIN: a machine learning approach to enhance the prediction of significant fibrosis or higher in metabolic dysfunction-associated steatotic liver disease. Am J Gastroenterol. 2025. https:\/\/doi.org\/10.14309\/ajg.0000000000003432.","journal-title":"Am J Gastroenterol"},{"key":"2362_CR74","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1136\/gutjnl-2025-335542","volume":"74","author":"G Feng","year":"2025","unstructured":"Feng G, Wong VW, Targher G, Byrne CD, Zheng MH. Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring. Gut. 2025;74:1741\u201350. https:\/\/doi.org\/10.1136\/gutjnl-2025-335542.","journal-title":"Gut"},{"key":"2362_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252313067","author":"T Mouskeftara","year":"2024","unstructured":"Mouskeftara T, Kalopitas G, Liapikos T, Arvanitakis K, Theocharidou E, Germanidis G, et al. A comprehensive analysis of liver lipidomics signature in adults with metabolic dysfunction-associated steatohepatitis-a pilot study. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms252313067.","journal-title":"Int J Mol Sci"},{"key":"2362_CR76","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00592-020-01612-7","volume":"58","author":"J Weyler","year":"2021","unstructured":"Weyler J, Verrijken A, Hornemann T, Vonghia L, Dirinck E, von Eckardstein A, et al. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease. Acta Diabetol. 2021;58:319\u201327. https:\/\/doi.org\/10.1007\/s00592-020-01612-7.","journal-title":"Acta Diabetol"},{"key":"2362_CR77","doi-asserted-by":"publisher","first-page":"G599","DOI":"10.1152\/ajpgi.00418.2015","volume":"311","author":"WJ Kwanten","year":"2016","unstructured":"Kwanten WJ, Vandewynckel YP, Martinet W, De Winter BY, Michielsen PP, Van Hoof VO, et al. Hepatocellular autophagy modulates the unfolded protein response and fasting-induced steatosis in mice. Am J Physiol Gastrointest Liver Physiol. 2016;311:G599-g609. https:\/\/doi.org\/10.1152\/ajpgi.00418.2015.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2362_CR78","doi-asserted-by":"publisher","first-page":"G77","DOI":"10.1152\/ajpgi.00301.2011","volume":"302","author":"K Kakisaka","year":"2012","unstructured":"Kakisaka K, Cazanave SC, Fingas CD, Guicciardi ME, Bronk SF, Werneburg NW, et al. Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. Am J Physiol Gastrointest Liver Physiol. 2012;302:G77-84. https:\/\/doi.org\/10.1152\/ajpgi.00301.2011.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2362_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13020267","author":"L Fernandes Silva","year":"2023","unstructured":"Fernandes Silva L, Vangipurapu J, Oravilahti A, M\u00e4nnist\u00f6 V, Laakso M. Plasma metabolite signatures in male carriers of genetic variants associated with non-alcoholic fatty liver disease. Metabolites. 2023. https:\/\/doi.org\/10.3390\/metabo13020267.","journal-title":"Metabolites"},{"key":"2362_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105088","volume":"102","author":"C Peleman","year":"2024","unstructured":"Peleman C, Francque S, Berghe TV. Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease: revisiting hepatic lipid peroxidation. EBioMedicine. 2024;102:105088. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105088.","journal-title":"EBioMedicine"},{"key":"2362_CR81","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1007\/s00204-019-02597-1","volume":"93","author":"H Jaeschke","year":"2019","unstructured":"Jaeschke H, Ramachandran A, Chao X, Ding WX. Emerging and established modes of cell death during acetaminophen-induced liver injury. Arch Toxicol. 2019;93:3491\u2013502. https:\/\/doi.org\/10.1007\/s00204-019-02597-1.","journal-title":"Arch Toxicol"},{"key":"2362_CR82","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrgastro.2017.21","volume":"14","author":"H Thomas","year":"2017","unstructured":"Thomas H. NAFLD: a critical role for the NLRP3 inflammasome in NASH. Nat Rev Gastroenterol Hepatol. 2017;14:197. https:\/\/doi.org\/10.1038\/nrgastro.2017.21.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2362_CR83","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm.3804","volume":"21","author":"YH Youm","year":"2015","unstructured":"Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21:263\u20139. https:\/\/doi.org\/10.1038\/nm.3804.","journal-title":"Nat Med"},{"key":"2362_CR84","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"RC Coll","year":"2015","unstructured":"Coll RC, Robertson AA, Chae JJ, Higgins SC, Mu\u00f1oz-Planillo R, Inserra MC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21:248\u201355. https:\/\/doi.org\/10.1038\/nm.3806.","journal-title":"Nat Med"},{"key":"2362_CR85","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3350\/cmh.2024.0315","volume":"30","author":"M Yan","year":"2024","unstructured":"Yan M, Man S, Ma L, Guo L, Huang L, Gao W. Immunological mechanisms in steatotic liver diseases: an overview and clinical perspectives. Clin Mol Hepatol. 2024;30:620\u201348. https:\/\/doi.org\/10.3350\/cmh.2024.0315.","journal-title":"Clin Mol Hepatol"},{"key":"2362_CR86","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, N\u00fa\u00f1ez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450\u20136. https:\/\/doi.org\/10.1038\/s41586-021-03362-0.","journal-title":"Nature"},{"key":"2362_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/nu16234151","author":"T Sakaguchi","year":"2024","unstructured":"Sakaguchi T, Nagahama Y, Hamada N, Singh SK, Mikami H, Maeda K, et al. Novel choline-deficient and 0.1%-methionine-added high-fat diet induces burned-out metabolic-dysfunction-associated steatohepatitis with inflammation by rapid immune cell infiltration on male mice. Nutrients. 2024. https:\/\/doi.org\/10.3390\/nu16234151.","journal-title":"Nutrients"},{"key":"2362_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100301","volume":"3","author":"AS Meijnikman","year":"2021","unstructured":"Meijnikman AS, Herrema H, Scheithauer TPM, Kroon J, Nieuwdorp M, Groen AK. Evaluating causality of cellular senescence in non-alcoholic fatty liver disease. JHEP Rep. 2021;3:100301. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100301.","journal-title":"JHEP Rep"},{"key":"2362_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57616-w","volume":"16","author":"K Du","year":"2025","unstructured":"Du K, Umbaugh DS, Wang L, Jun JH, Dutta RK, Oh SH, et al. Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction. Nat Commun. 2025;16:3038. https:\/\/doi.org\/10.1038\/s41467-025-57616-w.","journal-title":"Nat Commun"},{"key":"2362_CR90","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/pbc.24373","volume":"60","author":"JR Wu","year":"2013","unstructured":"Wu JR, Yuan LX, Ma ZG, Chen XX, Gu L, Gao J. GDF15-mediated upregulation of ferroportin plays a key role in the development of hyperferritinemia in children with hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2013;60:940\u20135. https:\/\/doi.org\/10.1002\/pbc.24373.","journal-title":"Pediatr Blood Cancer"},{"key":"2362_CR91","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41586-024-08305-z","volume":"637","author":"I Melero","year":"2025","unstructured":"Melero I, de Miguel Luken M, de Velasco G, Garralda E, Mart\u00edn-Liberal J, Joerger M, et al. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025;637:1218\u201327. https:\/\/doi.org\/10.1038\/s41586-024-08305-z.","journal-title":"Nature"},{"key":"2362_CR92","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi0759","volume":"15","author":"S Wang","year":"2023","unstructured":"Wang S, Friedman SL. Found in translation-fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). Sci Transl Med. 2023;15:eadi0759. https:\/\/doi.org\/10.1126\/scitranslmed.adi0759.","journal-title":"Sci Transl Med"},{"key":"2362_CR93","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cmet.2024.05.003","volume":"36","author":"P Horn","year":"2024","unstructured":"Horn P, Tacke F. Metabolic reprogramming in liver fibrosis. Cell Metab. 2024;36:1439\u201355. https:\/\/doi.org\/10.1016\/j.cmet.2024.05.003.","journal-title":"Cell Metab"},{"key":"2362_CR94","doi-asserted-by":"publisher","DOI":"10.1172\/jci166731","author":"T Yan","year":"2024","unstructured":"Yan T, Yan N, Xia Y, Sawaswong V, Zhu X, Dias HB, et al. Hepatocyte-specific CCAAT\/enhancer binding protein \u03b1 restricts liver fibrosis progression. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/jci166731.","journal-title":"J Clin Invest"},{"issue":"833","key":"2362_CR95","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1126\/scitranslmed.adx0368","volume":"18","author":"CN Yashaswini","year":"2026","unstructured":"Yashaswini CN, Cogliati B, Qin T, To T, Williamson T, Papp TE, Li K, Rasul R, Chen L, Lightstone A, Aghajanian H, Parhiz H, Wang S, Rurik JG, Epstein JA, Friedman SL. Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis. Sci Transl Med. 2026;18(833):368. https:\/\/doi.org\/10.1126\/scitranslmed.adx0368.","journal-title":"Sci Transl Med."},{"key":"2362_CR96","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.jhep.2024.06.008","volume":"81","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Dubourg J. Liver biopsy evaluation in MASH drug development: think thrice, act wise. J Hepatol. 2024;81:886\u201394. https:\/\/doi.org\/10.1016\/j.jhep.2024.06.008.","journal-title":"J Hepatol"},{"key":"2362_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2026.03.030","author":"ZM Younossi","year":"2026","unstructured":"Younossi ZM, Kalligeros M, Wong VW, Al-Naamani KM, Tacke F, Tsochatzis E, Crespo J, El-Kassas M, Bril F, Arrese M, Caussy C, Spearman CW, Gastaldelli A, Pessoa MG, Gadano A, Shubrook JH, Duseja A, Eguchi Y, Chan WK, Fan JG, Holleboom AG, Yu ML, Kim J, Kawaguchi T, Villela-Nogueira C, Oliveria CP, Kong AP, Lam B, Giles H, Betel M, Ong JP, Burra P, Yilmaz Y, Pearlman B, Buti M, Papatheodoridis G, Abreu ES, Abdelmalek M, Alkhouri N, Nader F, Stepanova M, Racila A, Paik J, Ivancovsky Wajcman D, Grinshpan LS, Roberts SK, Alqahtani SA, Zelber-Sagi S, Castera L, Henry L. Updated global consensus recommendations for risk stratification, treatment initiation, and response monitoring in metabolic dysfunction-associated steatotic liver disease. Clin Gastroenterol Hepatol. 2026. https:\/\/doi.org\/10.1016\/j.cgh.2026.03.030.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2362_CR98","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/hep.0000000000001112","volume":"81","author":"VL Chen","year":"2024","unstructured":"Chen VL, Morgan TR, Rotman Y, Patton HM, Cusi K, Kanwal F, et al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD practice guidance. Hepatology. 2024;81:312\u201320. https:\/\/doi.org\/10.1097\/hep.0000000000001112.","journal-title":"Hepatology"},{"key":"2362_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.08.023","author":"A Olveira","year":"2025","unstructured":"Olveira A, Crespo J, Iba\u00f1ez-Samaniego L, Gallego-Dur\u00e1n R, Calleja JL, Aller R, et al. Defining non-invasive criteria for indicating drug therapy in metabolic-associated steatotic liver disease in clinical practice. Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2025.08.023.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2362_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.12.001","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Nakajima A, Bugianesi E, Sebastiani G, Schattenberg JM, Adams LA, et al. Expert Delphi consensus on surrogate endpoints for treatment assessment in metabolic dysfunction-associated steatohepatitis. Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2025.12.001.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2362_CR101","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/MCG.0b013e31826df40a","volume":"47","author":"CE Ruhl","year":"2013","unstructured":"Ruhl CE, Everhart JE. Diurnal variation in serum alanine aminotransferase activity in the US population. J Clin Gastroenterol. 2013;47:165\u201373. https:\/\/doi.org\/10.1097\/MCG.0b013e31826df40a.","journal-title":"J Clin Gastroenterol"},{"key":"2362_CR102","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1515\/cclm-2013-0096","volume":"51","author":"A Carobene","year":"2013","unstructured":"Carobene A, Braga F, Roraas T, Sandberg S, Bartlett WA. A systematic review of data on biological variation for alanine aminotransferase, aspartate aminotransferase and \u03b3-glutamyl transferase. Clin Chem Lab Med. 2013;51:1997\u20132007. https:\/\/doi.org\/10.1515\/cclm-2013-0096.","journal-title":"Clin Chem Lab Med"},{"key":"2362_CR103","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/jgh.14311","volume":"34","author":"JC Chow","year":"2019","unstructured":"Chow JC, Wong GL, Chan AW, Shu SS, Chan CK, Leung JK, et al. Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness. J Gastroenterol Hepatol. 2019;34:241\u20138. https:\/\/doi.org\/10.1111\/jgh.14311.","journal-title":"J Gastroenterol Hepatol"},{"key":"2362_CR104","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2413258.","journal-title":"N Engl J Med"},{"key":"2362_CR105","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393:26\u201336. https:\/\/doi.org\/10.1056\/NEJMoa2416394.","journal-title":"N Engl J Med"},{"key":"2362_CR106","doi-asserted-by":"publisher","unstructured":"Theocharidou E, Germanidis G. Non-invasive tests for fibrotic MASH: Decision aids in MASH therapeutics and predictors of liver-related events. Med (NY) [Internet]. 2026 [cited 2026 Jun 15];7:100965. https:\/\/doi.org\/10.1016\/j.medj.2025.100965.","DOI":"10.1016\/j.medj.2025.100965"},{"key":"2362_CR107","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","volume":"69","author":"JF Dufour","year":"2020","unstructured":"Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut. 2020;69:1877\u201384. https:\/\/doi.org\/10.1136\/gutjnl-2019-319104.","journal-title":"Gut"},{"key":"2362_CR108","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jhep.2025.03.001","volume":"83","author":"G Issa","year":"2025","unstructured":"Issa G, Shang Y, Strandberg R, Hagstr\u00f6m H, Wester A. Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden. J Hepatol. 2025;83:643\u201351. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.001.","journal-title":"J Hepatol"},{"key":"2362_CR109","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","volume":"63","author":"P Dongiovanni","year":"2015","unstructured":"Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63:705\u201312. https:\/\/doi.org\/10.1016\/j.jhep.2015.05.006.","journal-title":"J Hepatol"},{"key":"2362_CR110","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamainternmed.2025.0115","volume":"185","author":"J Choi","year":"2025","unstructured":"Choi J, Nguyen VH, Przybyszewski E, Song J, Carroll A, Michta M, et al. Statin use and risk of hepatocellular carcinoma and liver fibrosis in chronic liver disease. JAMA Intern Med. 2025;185:522\u201330. https:\/\/doi.org\/10.1001\/jamainternmed.2025.0115.","journal-title":"JAMA Intern Med"},{"key":"2362_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03978-z","author":"B McGowan","year":"2025","unstructured":"McGowan B, Ciudin A, Baker JL, Busetto L, Dicker D, Fr\u00fchbeck G, et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03978-z.","journal-title":"Nat Med"},{"key":"2362_CR112","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jhep.2024.10.018","volume":"82","author":"V Ratziu","year":"2025","unstructured":"Ratziu V, Scanlan TS, Bruinstroop E. Thyroid hormone receptor-\u03b2 analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). J Hepatol. 2025;82:375\u201387. https:\/\/doi.org\/10.1016\/j.jhep.2024.10.018.","journal-title":"J Hepatol"},{"key":"2362_CR113","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41575-025-01096-2","volume":"22","author":"H Tilg","year":"2025","unstructured":"Tilg H, Targher G. Lessons from incretin-based therapy in MASH and obesity. Nat Rev Gastroenterol Hepatol. 2025;22:531\u20133. https:\/\/doi.org\/10.1038\/s41575-025-01096-2.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2362_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03799-0","author":"M Jara","year":"2025","unstructured":"Jara M, Norlin J, Kj\u00e6r MS, Almholt K, Bendtsen KM, Bugianesi E, et al. Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03799-0.","journal-title":"Nat Med"},{"key":"2362_CR115","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","volume":"23","author":"SA Harrison","year":"2025","unstructured":"Harrison SA, Frias JP, Lucas KJ, Reiss G, Neff G, Bollepalli S, et al. Safety and efficacy of efruxifermin in combination with a GLP-1 receptor agonist in patients with NASH\/MASH and type 2 diabetes in a randomized phase 2 study. Clin Gastroenterol Hepatol. 2025;23:103\u201313. https:\/\/doi.org\/10.1016\/j.cgh.2024.02.022.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2362_CR116","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jhep.2025.02.003","volume":"83","author":"Z Liu","year":"2025","unstructured":"Liu Z, Wei S, Jiang Y, Su W, Ma F, Cai G, et al. Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway. J Hepatol. 2025;83:630\u201342. https:\/\/doi.org\/10.1016\/j.jhep.2025.02.003.","journal-title":"J Hepatol"},{"key":"2362_CR117","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jhep.2024.12.006","volume":"82","author":"L Xiang","year":"2025","unstructured":"Xiang L, Wang G, Zhuang Y, Luo L, Yan J, Zhang H, et al. Safety and efficacy of GLP-1\/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study. J Hepatol. 2025;82:967\u201378. https:\/\/doi.org\/10.1016\/j.jhep.2024.12.006.","journal-title":"J Hepatol"},{"key":"2362_CR118","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jhep.2022.12.025","volume":"78","author":"V Ratziu","year":"2023","unstructured":"Ratziu V, Charlton M. Rational combination therapy for NASH: insights from clinical trials and error. J Hepatol. 2023;78:1073\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2022.12.025.","journal-title":"J Hepatol"},{"key":"2362_CR119","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/s2468-1253(24)00246-2","volume":"9","author":"R Loomba","year":"2024","unstructured":"Loomba R, Bedossa P, Grimmer K, Kemble G, Bruno Martins E, McCulloch W, et al. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2024;9:1090\u2013100. https:\/\/doi.org\/10.1016\/s2468-1253(24)00246-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2362_CR120","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","volume":"30","author":"V Raverdy","year":"2024","unstructured":"Raverdy V, Tavaglione F, Chatelain E, Lassailly G, De Vincentis A, Vespasiani-Gentilucci U, et al. Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30:3624\u201333. https:\/\/doi.org\/10.1038\/s41591-024-03283-1.","journal-title":"Nat Med"},{"key":"2362_CR121","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jhep.2025.02.032","volume":"82","author":"PK Luukkonen","year":"2025","unstructured":"Luukkonen PK. Subtypes of MASLD confer distinct clinical trajectories. J Hepatol. 2025;82:1138\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2025.02.032.","journal-title":"J Hepatol"},{"key":"2362_CR122","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/liv.15078","volume":"42","author":"H Lin","year":"2022","unstructured":"Lin H, Wong GL, Whatling C, Chan AW, Leung HH, Tse CH, et al. Association of genetic variations with NAFLD in lean individuals. Liver Int. 2022;42:149\u201360. https:\/\/doi.org\/10.1111\/liv.15078.","journal-title":"Liver Int"},{"key":"2362_CR123","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/hep.28697","volume":"65","author":"JC Leung","year":"2017","unstructured":"Leung JC, Loong TC, Wei JL, Wong GL, Chan AW, Choi PC, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2017;65:54\u201364. https:\/\/doi.org\/10.1002\/hep.28697.","journal-title":"Hepatology"},{"key":"2362_CR124","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jhep.2024.06.030","volume":"81","author":"A Ahmed","year":"2024","unstructured":"Ahmed A, Cule M, Bell JD, Sattar N, Yaghootkar H. Differing genetic variants associated with liver fat and their contrasting relationships with cardiovascular diseases and cancer. J Hepatol. 2024;81:921\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2024.06.030.","journal-title":"J Hepatol"},{"key":"2362_CR125","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","volume":"378","author":"NS Abul-Husn","year":"2018","unstructured":"Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med. 2018;378:1096\u2013106. https:\/\/doi.org\/10.1056\/NEJMoa1712191.","journal-title":"N Engl J Med"},{"key":"2362_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-025-01394-8","author":"RM Mancina","year":"2025","unstructured":"Mancina RM, Valenti L, Romeo S. Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism. Nat Metab. 2025. https:\/\/doi.org\/10.1038\/s42255-025-01394-8.","journal-title":"Nat Metab"},{"key":"2362_CR127","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1056\/NEJMc2402341","volume":"391","author":"E Fabbrini","year":"2024","unstructured":"Fabbrini E, Rady B, Koshkina A, Jeon JY, Ayyar VS, Gargano C, et al. Phase 1 trials of PNPLA3 siRNA in I148M homozygous patients with MAFLD. N Engl J Med. 2024;391:475\u20136. https:\/\/doi.org\/10.1056\/NEJMc2402341.","journal-title":"N Engl J Med"},{"key":"2362_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.12.046","author":"J Armisen","year":"2025","unstructured":"Armisen J, Rauschecker M, Sarv J, Liljeblad M, Wernevik L, Niazi M, et al. AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2024.12.046.","journal-title":"J Hepatol"},{"key":"2362_CR129","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jhep.2025.05.031","volume":"83","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Taubel J, Badri P, Bond S, Makarova N, Zhao W, et al. Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis. J Hepatol. 2025;83:838\u201348. https:\/\/doi.org\/10.1016\/j.jhep.2025.05.031.","journal-title":"J Hepatol"},{"key":"2362_CR130","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16186","volume":"45","author":"D Lind\u00e9n","year":"2025","unstructured":"Lind\u00e9n D, Tesz G, Loomba R. Targeting PNPLA3 to treat MASH and MASH related fibrosis and cirrhosis. Liver Int. 2025;45:e16186. https:\/\/doi.org\/10.1111\/liv.16186.","journal-title":"Liver Int"},{"key":"2362_CR131","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","volume":"20","author":"L Hammerich","year":"2023","unstructured":"Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis. Nat Rev Gastroenterol Hepatol. 2023;20:633\u201346. https:\/\/doi.org\/10.1038\/s41575-023-00807-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2362_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.02.039","author":"A de Zawadzki","year":"2025","unstructured":"de Zawadzki A, Leeming DJ, Sanyal AJ, Anstee QM, Schattenberg JM, Friedman SL, et al. Hot and cold fibrosis: the role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.02.039.","journal-title":"J Hepatol"},{"key":"2362_CR133","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.03.010","author":"T Kisseleva","year":"2025","unstructured":"Kisseleva T, Ganguly S, Murad R, Wang A, Brenner DA. Regulation of hepatic stellate cell phenotypes in metabolic dysfunction-associated steatohepatitis. Gastroenterology. 2025. https:\/\/doi.org\/10.1053\/j.gastro.2025.03.010.","journal-title":"Gastroenterology"},{"key":"2362_CR134","doi-asserted-by":"publisher","DOI":"10.1172\/jci186421","author":"F Colella","year":"2025","unstructured":"Colella F, Henderson NC, Ramachandran P. Dissecting the mechanisms of MASLD fibrosis in the era of single-cell and spatial omics. J Clin Invest. 2025. https:\/\/doi.org\/10.1172\/jci186421.","journal-title":"J Clin Invest"},{"key":"2362_CR135","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s41590-025-02255-y","volume":"26","author":"OP Martin","year":"2025","unstructured":"Martin OP, Wallace MS, Oetheimer C, Patel HB, Butler MD, Wong LP, et al. Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesis. Nat Immunol. 2025;26:1596\u2013611. https:\/\/doi.org\/10.1038\/s41590-025-02255-y.","journal-title":"Nat Immunol"},{"key":"2362_CR136","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/s2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kj\u00e6r MS, Krarup N, et al. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:511\u201322. https:\/\/doi.org\/10.1016\/s2468-1253(23)00068-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2362_CR137","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S2468-1253(25)00260-2","volume":"11","author":"W Li","year":"2026","unstructured":"Li W, Alazawi W, Loomba R. Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis. Lancet Gastroenterol Hepatol. 2026;11:150\u201362. https:\/\/doi.org\/10.1016\/S2468-1253(25)00260-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2362_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-026-01187-8","author":"ME Rinella","year":"2026","unstructured":"Rinella ME, Sookoian S. Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management. Nat Rev Gastroenterol Hepatol. 2026. https:\/\/doi.org\/10.1038\/s41575-026-01187-8.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2362_CR139","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502242","author":"M Noureddin","year":"2025","unstructured":"Noureddin M, Rinella ME, Chalasani NP, Neff GW, Lucas KJ, Rodriguez ME, et al. Efruxifermin in compensated liver cirrhosis caused by MASH. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2502242.","journal-title":"N Engl J Med"},{"key":"2362_CR140","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMe2505834","volume":"392","author":"G Garcia-Tsao","year":"2025","unstructured":"Garcia-Tsao G. Redefining end points in MASH cirrhosis. N Engl J Med. 2025;392:2475\u20137. https:\/\/doi.org\/10.1056\/NEJMe2505834.","journal-title":"N Engl J Med"},{"key":"2362_CR141","doi-asserted-by":"publisher","DOI":"10.1172\/jci186423","author":"B Schnabl","year":"2025","unstructured":"Schnabl B, Damman CJ, Carr RM. Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations. J Clin Invest. 2025. https:\/\/doi.org\/10.1172\/jci186423.","journal-title":"J Clin Invest"},{"key":"2362_CR142","doi-asserted-by":"publisher","first-page":"C1637","DOI":"10.1152\/ajpcell.00951.2024","volume":"328","author":"MS Kuchay","year":"2025","unstructured":"Kuchay MS, Choudhary NS, Ramos-Molina B. Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease. Am J Physiol Cell Physiol. 2025;328:C1637-c1666. https:\/\/doi.org\/10.1152\/ajpcell.00951.2024.","journal-title":"Am J Physiol Cell Physiol"},{"key":"2362_CR143","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13646","volume":"25","author":"X Su","year":"2024","unstructured":"Su X, Chen S, Liu J, Feng Y, Han E, Hao X, et al. Composition of gut microbiota and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Obes Rev. 2024;25:e13646. https:\/\/doi.org\/10.1111\/obr.13646.","journal-title":"Obes Rev"},{"key":"2362_CR144","doi-asserted-by":"publisher","unstructured":"Tang Y, Kuang J, Xia X, Yao C, Zhou Z, Liu J, et al. Targeting microbiota-generated acetaldehyde to prevent progression of metabolic dysfunction-associated steatotic liver disease. Cell Metab [Internet]. Cell Press; 2026 [cited 2026 Jun 15];38:1172\u201386.e9. https:\/\/doi.org\/10.1016\/j.cmet.2026.01.021.","DOI":"10.1016\/j.cmet.2026.01.021"},{"key":"2362_CR145","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1362694","volume":"11","author":"AS Silva-Sperb","year":"2024","unstructured":"Silva-Sperb AS, Moraes HA, Barcelos STA, de Moura BC, Longo L, Michalczuk MT, et al. Probiotic supplementation for 24\u2009weeks in patients with non-alcoholic steatohepatitis: the PROBILIVER randomized clinical trial. Front Nutr. 2024;11:1362694. https:\/\/doi.org\/10.3389\/fnut.2024.1362694.","journal-title":"Front Nutr"},{"key":"2362_CR146","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3748\/wjg.v30.i8.833","volume":"30","author":"XX Qiu","year":"2024","unstructured":"Qiu XX, Cheng SL, Liu YH, Li Y, Zhang R, Li NN, et al. Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: mechanism, clinical evidence, and prospect. World J Gastroenterol. 2024;30:833\u201342. https:\/\/doi.org\/10.3748\/wjg.v30.i8.833.","journal-title":"World J Gastroenterol"},{"key":"2362_CR147","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41564-024-01902-8","volume":"10","author":"T Zhang","year":"2025","unstructured":"Zhang T, Wang W, Li J, Ye X, Wang Z, Cui S, et al. Free fatty acid receptor 4 modulates dietary sugar preference via the gut microbiota. Nat Microbiol. 2025;10:348\u201361. https:\/\/doi.org\/10.1038\/s41564-024-01902-8.","journal-title":"Nat Microbiol"},{"key":"2362_CR148","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1056\/NEJMra2403308","volume":"393","author":"L Castera","year":"2025","unstructured":"Castera L, Rinella ME, Tsochatzis EA. Noninvasive assessment of liver fibrosis. N Engl J Med. 2025;393:1715\u201329. https:\/\/doi.org\/10.1056\/NEJMra2403308.","journal-title":"N Engl J Med"},{"key":"2362_CR149","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/hep.29302","volume":"66","author":"G Xiao","year":"2017","unstructured":"Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66:1486\u2013501. https:\/\/doi.org\/10.1002\/hep.29302.","journal-title":"Hepatology"},{"key":"2362_CR150","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","volume":"73","author":"Y Vali","year":"2020","unstructured":"Vali Y, Lee J, Boursier J, Spijker R, L\u00f6ffler J, Verheij J, et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2020;73:252\u201362. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.036.","journal-title":"J Hepatol"},{"key":"2362_CR151","doi-asserted-by":"publisher","unstructured":"Marti-Aguado D, Carot-Sierra JM, Villalba-Ortiz A, Siddiqi H, Vallejo-Vigo RM, Lara-Romero C, et al. Identification of candidates for MASLD treatment with indeterminate vibration-controlled transient elastography. Clin Gastroenterol Hepatol. 2025;23:1183\u201393.e5. https:\/\/doi.org\/10.1016\/j.cgh.2024.10.014.","DOI":"10.1016\/j.cgh.2024.10.014"},{"key":"2362_CR152","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","volume":"79","author":"JX Liang","year":"2023","unstructured":"Liang JX, Ampuero J, Niu H, Imajo K, Noureddin M, Behari J, et al. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. J Hepatol. 2023;79:592\u2013604. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.025.","journal-title":"J Hepatol"},{"key":"2362_CR153","doi-asserted-by":"publisher","unstructured":"Pennisi G, Enea M, Pandolfo A, Celsa C, Antonucci M, Ciccioli C, et al. AGILE 3+ score for the diagnosis of advanced fibrosis and for predicting liver-related events in NAFLD. Clin Gastroenterol Hepatol. 2023;21:1293\u2013302.e5. https:\/\/doi.org\/10.1016\/j.cgh.2022.06.013.","DOI":"10.1016\/j.cgh.2022.06.013"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02362-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02362-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02362-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:06:34Z","timestamp":1790366794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02362-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":153,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2362"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02362-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.K. has received honoraria for lectures from AstraZeneca, Sanofi, Boehringer Ingelheim, Pharmaserve Lilly, Menarini, and Novo Nordisk, for advisory boards from Novo Nordisk, Roche, Sanofi and Boehringer Ingelheim, and has participated in sponsored studies by Eli-Lilly, AstraZeneca and Novo Nordisk; E.A.T. received advisory fees from Boehringer Ingelheim, Siemens, Novo Nordisk, MSD, Madrigal and speaker fees from Abbvie, Dr. Falk, Boehringer Ingelheim, Echosens and Novo Nordisk. S.M.F. has been a lecturer for AbbVie, Allergan, Bayer, Eisai, Genfit, Gilead Sciences, Janssens Cilag, Intercept, Inventiva, Merck Sharp & Dome, Novo Nordisk, Promethera, Siemens. He has acted as consultant for AbbVie, Actelion, Aelin Therapeutics, AgomAb, Aligos Therapeutics, Allergan, Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristoll-Meyers Squibb, CSL Behring, Coherus, Echosens, Eisai, Enyo, Galapagos, Galmed, Genetech, Genfit, Genflow Bio, Gilead Sciences, Intercept, Inventiva, Janssens Pharmaceutica, Julius Clinical, Madrigal, Medimmune, Merck Sharp & Dome, NGM Bio, Novartis, Novo Nordisk, PRO.MED.CS, Promethera, Roche. His institution has received grants from Astellas, Falk Pharma, Genfit, Gilead Sciences, GlympsBio, Janssens Pharmaceutica, Inventiva, Merck Sharp & Dome, Pfizer, Roche. Other authors report no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ET and KA reviewed the literature and wrote the first version of the manuscript. TK, EM, SF and GG reviewed the literature and edited the manuscript. All authors have read and approved the final version of the manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}